期刊文献+

Aβ_(1~42)致老年性痴呆大鼠海马神经元细胞外信号调节激酶1,2的表达 被引量:4

Expressions of ERK1 and ERK2 in the hippocampus of rats with Aβ_(1~42) injected model of Alzheimer disease
原文传递
导出
摘要 目的:建立老年性痴呆大鼠模型,观察老年性痴呆大鼠海马神经元细胞外信号调节激酶1,2表达的变化,探讨其在老年性痴呆发病机制中的作用。方法:采用立体定向下双侧海马注射Aβ1~42建立老年性痴呆动物模型,经Y型电迷宫试验测试其行为学,采用免疫组织化学、蛋白印迹等方法观察细胞外信号调节激酶1,2表达变化。结果:模型组大鼠学习记忆能力较对照组显著下降,免疫组化显示海马CA1区细胞外信号调节激酶1,2的免疫反应阳性神经元数目及细胞平均光密度值均显著减少,蛋白印迹显示模型组较对照组条带变细,灰度值变小,差异均有统计学意义(P〈0.05)。结论:海马神经元细胞外信号调节激酶1,2表达的减少可能参与了老年性痴呆的发病机制。 Objective To explore the roles of ERK1 and ERK2 in the pathogenesis of Alzheimer disease by establishing model of Alzheimer disease and observing the expressions of ERK1 and ERK2 in the hippocampus of Alzheimer disease rats. Methods Alzheimer disease model was established by injecting Aβ1~42 into the bilateral hippocampus of rats. The learning and memory abilities of action were studied with Y maze; the expressions of ERK1 and ERK2 in hippocampus CA1 were observed with immuno-histochemistry WB. Results Compared with control group, the abilities of learning and memory of Alzheimer disease rats obviously decreased; the numbers of ERK1 and ERK2 immunoreactive neurons within the hippocampus CA1 region in the model group were significantly lower; the band of ERK1 and ERK2 were thinner by WB in hippocampus in the model group (P〈0. 05). Conclusion The decreased expression of ERK in hippocampal neurons might participate in the pathogenesis of Alzheimer disease.
出处 《中华实用诊断与治疗杂志》 2009年第2期151-153,共3页 Journal of Chinese Practical Diagnosis and Therapy
关键词 老年性痴呆 细胞外信号调节激酶1 2 蛋白印迹 海马 大鼠 Alzheimer disease ERK1,2 Western Blot hippocampus rat
  • 相关文献

参考文献1

二级参考文献9

共引文献2

同被引文献40

  • 1丁新生.老年性痴呆的病理、发病机制及其诊断研究[J].中国临床康复,2004,8(19):3885-3887. 被引量:25
  • 2卢忠朋,王乃平,钟振国.三七总皂甙对淀粉样β_(25~35)肽诱导的NG108-15细胞老年性痴呆模型的保护作用(英文)[J].中国临床康复,2004,8(34):7876-7878. 被引量:20
  • 3覃仁安,罗佳波,黄竹英,罗佩霞,肖晓丽.复方丹参片对阿尔茨海默病大鼠学习记忆障碍和脑组织β-AP含量的影响[J].中华中医药杂志,2005,20(6):377-378. 被引量:24
  • 4李东晓,邓文龙.冰片促透作用研究进展[J].中药药理与临床,2007,23(1):87-88. 被引量:77
  • 5Jaturapatporn D, Isaac MG, McCleery J, et al. Aspirin, steroidal and non- steroidalanti. Inflammaory drugs for the treatment of Alzheimer' s disease [J]. Cochrane Data-base Syst Rev, 2012, (2) : CD006378.
  • 6Vellas B, Black R, Thai LJ, et al. AN1792 (QS0-21)-251 Study Team. Long-term Follow-up of patients immunized with AN1792 : reduced functional decline in antibody responders [J]. Curt Alzheimer Res, 2009,6(2) : 144-151.
  • 7Orgogozo JM, Gilman S, Dartigues JF, et al. Subaeute meningoencephalitis in a subset of patients with AD after A(beta) 42 immunization [J]. Neurology, 2008, 61 (1) :46-54.
  • 8Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunization in Alzheimer' s disease: follow-up of a randomised,placebo- controlled phase I trial [J]. Lancet, 2009,372(9634) : 216-223.
  • 9Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease [J]. Neurology, 2009,73(24) :2061-2070.
  • 10Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer' s disease treated with bapineuzumab : a retrospective analysis [J]. Lancet Neurol, 2012,11(3) :241-249.

引证文献4

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部